

## **Global Huntington's Disease Treatment Market Report and Forecast 2023-2031**

Market Report | 2023-04-15 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Huntington's Disease Treatment Market Report and Forecast 2023-2031

Global Huntington's Disease Treatment Market Outlook

The global Huntington's disease treatment market is likely to grow at a rate of 16.0% in the forecast period of 2023-2031. Driven by the growing demand and increasing R&D activities, the market is anticipated to be worth USD 1500.8 Million by 2031.

Huntington's Disease Treatment Market: Introduction

The global Huntington's disease treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. Huntington's disease is a rare, inherited neurodegenerative disorder that affects a small percentage of the global population. The lack of effective treatments for Huntington's disease has been a major challenge for healthcare providers and researchers worldwide. The report covers the market for Huntington's disease treatment and provides a detailed analysis of the market size, growth, and trends.

The Huntington's disease treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as gene therapy and RNA interference, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.

Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of Huntington's disease, potentially improving patient outcomes and reducing healthcare costs. As a result, the global Huntington's disease treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.

Huntington's Disease Epidemiology

Huntington's disease is a rare inherited disorder that affects the brain and nervous system. The disease is caused by a genetic mutation that leads to the progressive breakdown of nerve cells in the brain. Huntington's disease affects people of all races and ethnicities, with an estimated prevalence of 5-10 cases per 100,000 people worldwide.

The onset of Huntington's disease typically occurs in midlife, with symptoms appearing between the ages of 30 and 50 years. The disease is characterized by a progressive loss of motor control, cognitive decline, and psychiatric symptoms. Currently, there is no

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

cure for Huntington's disease, and the available treatments only provide symptomatic relief.

The prevalence of Huntington's disease varies across different regions of the world. The disease is more common in certain populations, such as those of European ancestry, and less common in others, such as those of Asian and African descent. In North America and Europe, the prevalence of Huntington's disease is estimated to be between 5 and 10 cases per 100,000 people, while in Asia and Africa, the prevalence is lower, at around 1 case per 100,000 people.

The incidence of Huntington's disease is also influenced by gender, with men and women being affected at similar rates. However, the age of onset may be slightly earlier in men than in women.

#### Huntington's Disease Treatment Market Segmentations

The market can be categorised into treatment method, diagnosis method, drug class, treatment channel, and major region.

##### Market Breakup by Treatment Method

- Symptomatic Treatment
- Disease-modifying Therapies
- Palliative Care Treatment
- Others

##### Market Breakup by Diagnosis Method

- Neurological Exams and Neuropsychological Tests
- Psychiatric Evaluation
- Brain-Imaging and Function Tests
- Genetic Counselling
- Predictive Genetic Tests
- Others

##### Market Breakup by Drug Class

- Mood Stabilizers
- Antipsychotic Drugs
- Antidepressants
- Others

##### Market Breakup by Treatment Channel

- Public
- Private

##### Huntington's Disease Treatment Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

#### Huntington's Disease Treatment Market Scenario

North America dominates the Huntington's disease treatment market, followed by Europe and the Asia Pacific. The high prevalence of Huntington's disease in North America and Europe, coupled with the favorable reimbursement policies, is driving the growth of the market in these regions. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about Huntington's disease and the rising healthcare expenditure in the region. The market is highly fragmented, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for Huntington's disease has led to the emergence of a large number of companies focusing on the development of innovative therapies for this disorder.

#### Key Players in the Global Huntington's Disease Treatment Market

The report gives an in-depth analysis of the key players involved in the Huntington's Disease Treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- H. Lundbeck A/S
  - Teva Pharmaceutical Industries Ltd.
  - Bausch Health Companies Inc.
  - Hetero Drugs Limited
  - Lupin Limited
  - Hikma Pharmaceuticals plc
  - Dr Reddy's Laboratories Ltd
  - Sun Pharmaceutical Industries Limited
  - SOM Biotech
  - Annexon, Inc.
- &nbsp;

#### **Table of Contents:**

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 Huntington's Disease Overview
  - 4.1 Guidelines and Stages
  - 4.2 Pathophysiology
  - 4.3 Screening and Diagnosis
  - 4.4 Treatment Pathway

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5 Patient Profile
  - 5.1 Patient Profile Overview
  - 5.2 Patient Psychology and Emotional Impact Factors
  - 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation and Regulatory Framework
  - 6.1 Emerging Therapies and Clinical Trials
  - 6.2 Patent Landscape
    - 6.2.1 Patent Overview
      - 6.2.1.1 Patent Status and Expiry
      - 6.2.1.2 Timelines from Drug Development to Commercial Launch
      - 6.2.1.3 New Drug Application
        - 6.2.1.3.1 Documentation and Approval Process
  - 6.3 Cost of Treatment
  - 6.4 Regulatory Framework
    - 6.4.1 Regulatory Overview
      - 6.4.1.1 US FDA
      - 6.4.1.2 EU EMA
      - 6.4.1.3 INDIA CDSCO
      - 6.4.1.4 JAPAN PMDA
      - 6.4.1.5 Others
- 7 Challenges and Unmet Needs
  - 7.1 Treatment Pathway Challenges
  - 7.2 Compliance and Drop-Out Analysis
  - 7.3 Awareness and Prevention Gaps
- 8 Global Huntington's Disease Treatment Market
  - 8.1 Global Huntington's Disease Treatment Market Overview
  - 8.2 Global Huntington's Disease Treatment Market Analysis
    - 8.2.1 Market Overview
      - 8.2.1.1 Global Huntington's Disease Treatment Market Historical Value (2016-2022)
      - 8.2.1.2 Global Huntington's Disease Treatment Market Forecast Value (2023-2031)
    - 8.2.2 Global Huntington's Disease Treatment Market by Treatment Method
      - 8.2.2.1 Market Overview
        - 8.2.2.1.1 Symptomatic Treatment
        - 8.2.2.1.2 Disease-modifying Therapies
        - 8.2.2.1.3 Palliative Care Treatment
        - 8.2.2.1.4 Others
    - 8.2.3 Global Huntington's Disease Treatment Market by Diagnosis Method
      - 8.2.3.1 Market Overview
        - 8.2.3.1.1 Neurological and Neuropsychological Tests
        - 8.2.3.1.2 Psychiatric Evaluation
        - 8.2.3.1.3 Brain-Imaging and Function Tests
        - 8.2.3.1.4 Genetic Counselling
        - 8.2.3.1.5 Predictive Genetic Tests
        - 8.2.3.1.6 Others
    - 8.2.4 Global Huntington's Disease Treatment Market by Drug Class
      - 8.2.4.1 Market Overview
        - 8.2.4.1.1 Mood Stabilizers

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.2.4.1.2 Antipsychotic Drugs
- 8.2.4.1.3 Antidepressants
- 8.2.4.1.4 Others
- 8.2.5 Global Huntington's Disease Treatment Market by Treatment Channel
  - 8.2.5.1 Market Overview
    - 8.2.5.1.1 Public
    - 8.2.5.1.2 Private
- 8.2.6 Global Huntington's Disease Treatment Market by Region
  - 8.2.6.1 Market Overview
    - 8.2.6.1.1 North America
    - 8.2.6.1.2 Europe
    - 8.2.6.1.3 Asia Pacific
    - 8.2.6.1.4 Middle East and Africa
    - 8.2.6.1.5 Latin America
- 9 North America Huntington's Disease Treatment Market
  - 9.1 Market Share by Country
    - 9.2 United States of America
      - 9.2.1 Historical Trend (2016-2022)
      - 9.2.2 Forecast Trend (2023-2031)
    - 9.3 Canada
      - 9.3.1 Historical Trend (2016-2022)
      - 9.3.2 Forecast Trend (2023-2031)
- 10 Europe Huntington's Disease Treatment Market
  - 10.1 Market Share by Country
    - 10.2 United Kingdom
      - 10.2.1 Historical Trend (2016-2022)
      - 10.2.2 Forecast Trend (2023-2031)
    - 10.3 Germany
      - 10.3.1 Historical Trend (2016-2022)
      - 10.3.2 Forecast Trend (2023-2031)
    - 10.4 France
      - 10.4.1 Historical Trend (2016-2022)
      - 10.4.2 Forecast Trend (2023-2031)
    - 10.5 Italy
      - 10.5.1 Historical Trend (2016-2022)
      - 10.5.2 Forecast Trend (2023-2031)
    - 10.6 Others
- 11 Asia Pacific Huntington's Disease Treatment Market
  - 11.1 Market Share by Country
    - 11.2 China
      - 11.2.1 Historical Trend (2016-2022)
      - 11.2.2 Forecast Trend (2023-2031)
    - 11.3 Japan
      - 11.3.1 Historical Trend (2016-2022)
      - 11.3.2 Forecast Trend (2023-2031)
    - 11.4 India
      - 11.4.1 Historical Trend (2016-2022)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.4.2 Forecast Trend (2023-2031)
- 11.5 ASEAN
  - 11.5.1 Historical Trend (2016-2022)
  - 11.5.2 Forecast Trend (2023-2031)
- 11.6 Australia
  - 11.6.1 Historical Trend (2016-2022)
  - 11.6.2 Forecast Trend (2023-2031)
- 11.7 Others
- 12 Latin America Huntington's Disease Treatment Market
  - 12.1 Market Share by Country
  - 12.2 Brazil
    - 12.2.1 Historical Trend (2016-2022)
    - 12.2.2 Forecast Trend (2023-2031)
  - 12.3 Argentina
    - 12.3.1 Historical Trend (2016-2022)
    - 12.3.2 Forecast Trend (2023-2031)
  - 12.4 Mexico
    - 12.4.1 Historical Trend (2016-2022)
    - 12.4.2 Forecast Trend (2023-2031)
  - 12.5 Others
- 13 Middle East and Africa Huntington's Disease Treatment Market
  - 13.1 Market Share by Country
  - 13.2 Saudi Arabia
    - 13.2.1 Historical Trend (2016-2022)
    - 13.2.2 Forecast Trend (2023-2031)
  - 13.3 United Arab Emirates
    - 13.3.1 Historical Trend (2016-2022)
    - 13.3.2 Forecast Trend (2023-2031)
  - 13.4 Nigeria
    - 13.4.1 Historical Trend (2016-2022)
    - 13.4.2 Forecast Trend (2023-2031)
  - 13.5 South Africa
    - 13.5.1 Historical Trend (2016-2022)
    - 13.5.2 Forecast Trend (2023-2031)
  - 13.6 Others
- 14 Global Huntington's Disease Treatment Market Dynamics
  - 14.1 Market Drivers and Constraints
  - 14.2 SWOT Analysis
  - 14.3 Porter's Five Forces Model
  - 14.4 Key Demand Indicators
  - 14.5 Key Price Indicators
  - 14.6 Industry Events, Initiatives & Trends
  - 14.7 Value Chain Analysis
- 15 Supplier Landscape
  - 15.1 H. Lundbeck A/S
    - 15.1.1 Company Overview
    - 15.1.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15.1.3 Demographic Reach and Achievements
- 15.1.4 Mergers and Acquisitions
- 15.1.5 Certifications
- 15.2 Teva Pharmaceutical Industries Ltd.
- 15.2.1 Company Overview
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 Bausch Health Companies Inc.
- 15.3.1 Company Overview
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Hetero Drugs Limited
- 15.4.1 Company Overview
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Lupin Limited
- 15.5.1 Company Overview
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 Hikma Pharmaceuticals plc
- 15.6.1 Company Overview
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 Dr. Reddy's Laboratories Ltd
- 15.7.1 Company Overview
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisitions
- 15.7.5 Certifications
- 15.8 Sun Pharmaceutical Industries Limited
- 15.8.1 Company Overview
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 SOM Biotech
- 15.9.1 Company Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 Annexon, Inc.
- 15.10.1 Company Overview
- 15.10.2 Product Portfolio
- 15.10.3 Demographic Reach and Achievements
- 15.10.4 Mergers and Acquisitions
- 15.10.5 Certifications
- 16 Global Huntington's Disease Treatment Market- Distribution Model (Additional Insight)
- 16.1 Overview
- 16.2 Potential Distributors
- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Payment Methods (Additional Insight)
- 17.1 Government Funded
- 17.2 Private Insurance
- 17.3 Out-of-Pocket

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



**Global Huntington's Disease Treatment Market Report and Forecast 2023-2031**

Market Report | 2023-04-15 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-15"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com